Navigation Links
BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting

Independent Study Indicates 20-50% Improvement in Post-Preservation Functional Recovery of Peripheral Blood Stem Cells for Cancer Therapy

BOTHELL, Wash., June 25, 2007 /PRNewswire-FirstCall/ -- BioLife Solutions Inc. , a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, today presented data from an independent study of its CryoStor family of cryopreservation media at the annual meeting of the International Society for Cellular Therapy in Sydney, Australia.

The presentation by BioLife scientists summarized the results of a recent study conducted by researchers at the Fred Hutchinson Cancer Research Center (FHCRC) and the University of Washington. BioLife's CryoStor preservation media was compared with a DMSO/HSA media formulation, currently considered the "gold standard" for cryopreservation of peripheral blood stem cells. Peripheral blood stem cells are the most common source of stem cells for transplantation to treat various blood disorders such as leukemia.

Highlighted metrics evaluated in the study included Colony Forming Units (CFU), a key indicator of the functional ability of cells to divide and replicate following cryopreservation, and total CD34+ cell recovery, a key marker of a subpopulation of undifferentiated progenitor cells that are of critical interest to researchers focused on hematopoietic cell therapies. The results of the study showed that BioLife's CryoStor technology platform produced a 20-50% relative improvement across these key parameters in comparison to the 10% DMSO standard preservation media utilized at FHCRC.

Shelly Heimfeld, director of the cellular therapy laboratory at the Fred Hutchinson Cancer Research Center, commented: "We were impressed by how much better the CryoStor patented media formulations improved the post-preservation recovery of CD34+ and colony-forming cells. We
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ties Between Physicians and Drug Companies Still Too Strong: the Prescription Project Offers Solutions to Prevent Conflicts of Interest
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference
Post Your Comments:
(Date:10/7/2008)...VYVANSE taken once-daily significantly,improved th... Oct. 7 /- Shire plc (LSE: ...aceutical company, today,announced that a study pu...linical Psychiatry found once-daily VYVANSE signif...isorder (ADHD) symptoms in adults within,the first...
(Date:10/7/2008)...swire/ -- Aerovance Inc. today reported,pharmacoki... its Aerovant,inhalation powder that demonstrate g...cy following asthma patients, inhalation of a sing...st of three doses investigated in,Aerovance,s Phas...gin early,next year. Evidence gathered from noncli...
(Date:10/7/2008)...ed in Stage A of Trial Assessing Regimen of Bav...taxel -, TUSTIN, Calif., Oct. 7 /PRNewswire-First... PPHM ), a clinical stage biopharmaceutical,compan...nt of cancer and,hepatitis C virus (HCV) infection... in the first stage of a Phase II trial of bavitux...
(Date:10/6/2008)...wire-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: VRUS...ining the,Company as Vice President of Investor Re...ll be responsible for all investor relations,funct...fficer Kurt,Leutzinger., Most recently, Dr. Smith...lyst at JPMorgan Securities, and has been an analy...
Breaking Medicine Technology:Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3CSIRO enlisted to avert global wheat supply crisis 4432 1CSIRO enlisted to avert global wheat supply crisis 4432 2Oregon Based First Pacific Corporation Launches New Integrated 3 D Charting Program for Dentists 25343 1Oregon Based First Pacific Corporation Launches New Integrated 3 D Charting Program for Dentists 25343 2Resolution Health Introduces Womens Health and Wellness Action Campaign 25340 1Resolution Health Introduces Womens Health and Wellness Action Campaign 25340 2Resolution Health Introduces Womens Health and Wellness Action Campaign 25340 3Resolution Health Introduces Womens Health and Wellness Action Campaign 25340 4Tiny molecule helps control blood vessel development UT Southwestern researchers find 25337 1Tiny molecule helps control blood vessel development UT Southwestern researchers find 25337 2
... 23, 2007 /PRNewswire/ -- Researchers at,the Medic...ced the,results of a two-year study, which tested ...s Nerve Stimulation),Therapy(TM) in patients with ...f which Mark S. George, M.D., MUSC Distinguished,P...s is a lead,author, will appear in the April 2007 ...
...enchymal cells in bone marrow supply,leukemic cell...ritical nutrient when it is depleted by the cancer... /PRNewswire/ -- The cancer drug,asparaginase fail...tic leukemia (ALL) because molecules released by c...ect of that drug,according to investigators at St...
Other Medicine Technology:MUSC Research Offers Hope for Those Resistant to Depression,Treatment 2Leukemic Cells Find Safe Haven in Bone Marrow 2Leukemic Cells Find Safe Haven in Bone Marrow 3
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...xins can be removed and pollutants can be trapped ...rding to a recent study. The local water quality c...ncept of rain gardens has been around for 10 to 15... regard to the subject. US researchers at the Univ...
...dia has now become a testing ground for nurses who...g on the part if the Indian State Government of Ke...n (NCLEX) may be conducted in Kerala by the US. T...ion, whose membership comprises the boards of nurs...
...ber Norman, 12-year-old girl died after eating a s... assumed that it was a strawberry cream cake but h...zil nut. She suddenly developed difficulty in bre...ss in an hour’s time. She was immediately rushed t...
...e top rank with regard to Canada's health system h...he patients in the province expressing low satisfa...st health system in the country appears to exist i...f patient satisfaction and performance. The Confer...
Other Medicine News:
Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches.
Size: Large. 24.50 mm by 26.00 mm. Clear lucite. Supplied sterile.
Size: 2.3 x 6.4 x 80 mm. Storz offers the original Scleral Sponge II line designed by Harvey A. Lincoff, M.D. The material is a closed cell sponge which is non-toxic and non-antigenic. Implants are
Size: 5.0 x 80 mm. Storz offers the original Scleral Sponge II line designed by Harvey A. Lincoff, M.D. The material is a closed cell sponge which is non-toxic and non-antigenic. Implants are soft wi
Medicine Products: